1. Home
  2. TCRX vs SCLX Comparison

TCRX vs SCLX Comparison

Compare TCRX & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$0.79

Market Cap

67.3M

Sector

Health Care

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$6.85

Market Cap

55.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCRX
SCLX
Founded
2018
2011
Country
United States
United States
Employees
N/A
34
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.3M
55.1M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TCRX
SCLX
Price
$0.79
$6.85
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
888.0K
106.3K
Earning Date
05-08-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
12.28
N/A
EPS
N/A
N/A
Revenue
$10,325,000.00
N/A
Revenue This Year
N/A
$122.52
Revenue Next Year
$19.81
$186.30
P/E Ratio
N/A
N/A
Revenue Growth
266.65
N/A
52 Week Low
$0.83
$4.20
52 Week High
$2.57
$34.27

Technical Indicators

Market Signals
Indicator
TCRX
SCLX
Relative Strength Index (RSI) 37.24 41.02
Support Level N/A $5.72
Resistance Level $1.21 $7.77
Average True Range (ATR) 0.10 1.02
MACD -0.02 -0.26
Stochastic Oscillator 0.81 4.02

Price Performance

Historical Comparison
TCRX
SCLX

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: